Rigvir® for Ovarian Cancer: Invented in 1950s To Kill Cancer Cells Without Affecting Healthy Ones, Registered in Latvia in 2004, Effectively Applied in Germany
Rigvir® medicine is an integral part of virotherapy. Virotherapy implies treating tumours and metastases with the help of non-pathogenic viruses, and Rigvir® is the first officially recognized. Non-pathogenic virus means that no other disease will appear as a result of Rigvir® injection.
Rigvir® is used to conquer different cancer types, including ovarian.
Rigvir® history has begun in the 1950–60s and stretched out through time and borders. Officially, Rigvir® was registered in 2004 (Latvia), and then it was adopted by Georgia in 2015 and Armenia in 2016.
Although it was officially registered in 2004, a clinic in Germany started to apply it successfully for its patients. It managed to treat 3000+ patients with cancer since then and became popular among international patients. Why?
Unlike other common cancer therapies, Rigvir® doesn’t damage healthy cells of your body. When you get a Rigvir® injection, the medicine scans your body to detect and destroy the malignant cells. You can use virotherapy for ovarian cancer as the major therapy, or as an additional treatment to radio or chemotherapy.
Clinical Trials Have Provided Almost Zero Side Effects and Effectiveness for Ovarian Cancer And Other Types
Side effects of Rigvir® is what most patients are usually concerned about. The major one recorded is an insignificant temperature rise up to 37.5°C/99.5°F that lasted for up to three days. Moreover, only a minority of patients face it, so there’s a chance you’ll face none.
Since 1968 some clinical trials have been conducted to prove Rigvir® healing power. 415 melanoma patients received the treatment, and their survival rates improved. Further clinical experience proved that Rigvir® can treat:
- Ovarian cancer
- Kidney cancer
- Prostate cancer
- Bladder cancer
- Prostate cancer etc.
The latest publication about virotherapy in Melanoma Research, a peer-reviewed medical journal, confirms that survival rates of Rigvir® patients rose in 4-6 times.
Provide 6 Documents To Get Qualified For Virotherapy for Ovarian Cancer in Germany
You can also conquer the disease with virotherapy for ovarian cancer. Remember that your case is like no others. Therefore, the oncologists should first assess your case at the clinic in Germany to see whether you qualify for Rigvir® therapy. To do that they will first ask you to provide the following medical documents:
- Cytological findings
- Histopathological findings
- Blood count (including white blood cells) no older than 2 weeks
- ALT and analysis for creatinine
You’ll get the feedback from the support agent in 2–3 days which are needed for the free case assessment.
You may be willing to know who will evaluate your case. The answer is — highly experienced oncologists from Germany, who have already treated 3,000 cancer patients since 2000. That’s why we recommend you to visit Germany: since Rigvir® was invented in the 1950s, Germany has deepened its knowledge and practical skills to provide patients diagnosed with cancer with effective virotherapy.
Moreover, virotherapy isn’t the single treatment the German clinic provides. The doctors there apply holistic approach towards fighting cancer, that’s why except for Rigvir® injections, you’ll get a range of additional therapies to enhance your treatment and heal body and soul.
7 Days in Germany For Virotherapy for Ovarian Cancer: Rigvir® Injections, 24/7 Support and Additional Therapies To Boost Your Therapy
Your virotherapy starts with 7-day package. It’s highly diverse, and includes mental therapy as well as body treatment:
- Rigvir® injections
- Conducting new health tests to adjust your treatment process accordingly
- Nutritious meals with consideration of your specific features
- Consultations with highly professional doctors on a daily basis
- Comfortable lodging
- Transfers from/to Munich International Airport
This package costs approximately EUR 6,000 (USD 6,670). The price can vary based on additional therapies you may be prescribed:
- Only healthy food enriched with vitamins and other nutrients under your detox programme
- Receiving hormone-imitating drug Buserelin (if it is considered to be effective)
- Hyperthermia and Thermotherapy to expose you to high temperatures to reduce pain and increase the effectiveness of virotherapy
If you’re wishing to know the full scope of available therapies, click the button below for our manager to contact you asap within 24 hours and explain them all in detail.
When you arrive at home, the main task for you is to maintain the results achieved at the German clinic under control of your local oncologist. Such observance increases your chances for recovery and is necessary for the whole virotherapy process. You may be also invited to visit Germany once more for additional virotherapy course.
Willing to know whether Rigvir® can help to treat your ovarian cancer case? Click the button below to have a quick consultation or fill in the form on the right if you’re visiting our website from a desktop. We’ll be happy to assist and we do it with no charge.
List of References
- Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece, Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100.
- “Adapted ECHO-7 Virus RigVir Immunotherapy (oncolytic Virotherapy) Prolongs Survival in Melanoma Patients after Surgical Excision of the Tumour in a Retrospective Study.” Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurgis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina. Melanoma Research: October 2015 - Volume 25 - Issue 5 - p 421–426.
- Alberts, P., E. Olmane, L. Brokāne, Z. Krastiņa, M. Romanovska, K. Kupčs, S. Isajevs, G. Proboka, R. Erdmanis, J. Nazarovs, and D. Venskus, Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS, 2016. 124(10): p. 896-904.